Skip to main content
Toggle navigation
Login
Search
Home
Program Book
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Like
Tweet
Elpitha Soussou
Poster(s):
(353) Talazoparib Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: Safety Analyses From the Randomized, Placebo-Controlled, Phase 3 TALAPRO-2 Study
Wednesday, April 3, 2024
5:00 PM – 7:00 PM
ET
(354) Efficacy and Safety of Elranatamab in Black Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the Magnestimm Studies
Wednesday, April 3, 2024
5:00 PM – 7:00 PM
ET
(355) Efficacy of elranatamab and teclistamab in triple-class exposed/refractory multiple myeloma (TCE/R MM): A matching-adjusted indirect comparison (MAIC)
Wednesday, April 3, 2024
5:00 PM – 7:00 PM
ET
(356) Clinical Factors Associated with Cytokine Release Syndrome (CRS) and Elranatamab (ELRA) Dosing Recommendations After a Dose Interruption (DI)
Wednesday, April 3, 2024
5:00 PM – 7:00 PM
ET
(357) Elranatamab monotherapy in patients with relapsed or refractory multiple myeloma: updated long-term efficacy and safety from MagnetisMM-3
Wednesday, April 3, 2024
5:00 PM – 7:00 PM
ET
(358) Exposure-Safety Analyses of Talazoparib in Combination With Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in TALAPRO-2 Trial
Wednesday, April 3, 2024
5:00 PM – 7:00 PM
ET